2007 australian bio investment forum, page-6

In context, a disease incidence of 4.5 per 100,000 ain't too bad.

Chronic Myeloid Leukaemia (CML) has an incidence in the USA of approximately 2 per 100,000 (i.e. rarer than liver cancer).

Gleevec (Novartis) is a blockbuster that generates most of its revenue from prescription to treat CML.

Sales of Gleevec were US$2.5 BILLION in 2006.

So there you go.....a disease with an indidence of 2 per 100,000 can generate the bulk of US$2.5 BILLION in annual sales...............

Put that in ya PI-88 pipe and smoke it!

Short sellers BEWARE!